BCM
TAK icon

Brookstone Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Brookstone Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,924
Closed -$401K – 784
2021
Q2 		$401K Buy
23,924
+10,443
+77% +$178K 0.01% 520
2021
Q1 		$246K Buy
+13,481
New +$243K 0.01% 433

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brookstone Capital Management's TAK Position: Q3 2021 in Review

Brookstone Capital Management sold out of Takeda Pharmaceutical (TAK) in Q3 2021, closing a stake of 23,924 shares — an estimated $401K sold.

Brookstone Capital Management first reported a position in TAK in Q1 2021 and held it in 2 quarters. The position peaked at $401K in Q2 2021. 292 funds tracked by Wall St. Rank hold TAK as of Q3 2021.

  • Brookstone Capital Management reported no remaining Takeda Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Brookstone Capital Management sold 23,924 Takeda Pharmaceutical shares in Q3 2021, an estimated $401K.
  • Brookstone Capital Management first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 2 quarters.
  • Brookstone Capital Management's Takeda Pharmaceutical position peaked at $401K in Q2 2021.
  • 292 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2021.

Based on Brookstone Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.